Harnessing the brain’s immune system to fight neurodegeneration

CereSpir is targeting the emerging field of immuno-neurology via a novel mechanism for the treatment of Parkinson’s disease and other neurodegenerative diseases

CereSpir has the most advanced therapeutic agent targeting LRRK2 neurotoxicity and the only AICD inhibitor in development

• CERESPIR INCORPORATED Identifies Possible Link Between COVID-19 Induced Brain Inflammation and Acute Respiratory Stress Syndrome Via Breakdown of the Blood-Brain Barrier
• CERESPIR INCORPORATED Assembles World Class Clinical Advisory Board Chaired by Professor Robert A. Hauser to Support CERESPIR’S Parkinson’s Disease Development Program for Itanapraced
• CERESPIR INCORPORATED and the NATIONAL NEUROSCIENCE INSTITUTE SINGAPORE Announce Positive Data Showing Beneficial Effects of CERESPIR’s Clinical Stage Compound Itanapraced in a LRRK2 Model of Parkinson’s Disease